Solebury Trout Talks Titelbild

Solebury Trout Talks

Solebury Trout Talks

Von: Solebury Trout Talks
Jetzt kostenlos hören, ohne Abo

Nur 0,99 € pro Monat für die ersten 3 Monate

Danach 9.95 € pro Monat. Bedingungen gelten.

Über diesen Titel

 Solebury Trout partners with private and public companies across sectors, helping management teams tackle complex investor relations challenges, capitalize on corporate communications opportunities, access the market and prepare for capital raising. More than 60 professionals with expertise in investor relations, equity research, portfolio management, private equity, investment banking and corporate communications work at Solebury Trout. The company was formed through the combination of Solebury Communications with the Trout Group, the premier investor relations and strategic advisory firm serving the biotechnology industry, providing corporate access and hosting dozens of well-attended conferences and thought leader events. Solebury Trout is affiliated with leading equity capital markets advisory firm Solebury Capital, which in 2017 advised on nearly 40 percent of the IPO proceeds in the U.S., and is owned by PNC, one of the largest diversified financial institutions in the country.All rights reserved Wissenschaft
Folgen
  • Jonathan Solomon, BiomX - Part of the Nametag Series

    Jonathan Solomon, BiomX - Part of the Nametag Series
    Dec 15 2020
    Prior to his role in BiomX, Mr. Solomon was a co-founder, president, and CEO of ProClara (formerly NeuroPhage), which is pioneering an approach to treating neurodegenerative diseases. Under his leadership, the company raised more than $100 million and launched an ongoing clinical trial related to Alzheimer’s disease. Prior to that, he was selected to participate in the elite Israeli Defense Forces ‘Talpiot’ program, graduated as class valedictorian, and served for 10 years in a classified military unit. Mr. Solomon holds a B.Sc. magna cum laude in Physics and Mathematics from the Hebrew University, an M.Sc. summa cum laude in Electrical Engineering from Tel Aviv University, and an M.B.A. with honors from the Harvard Business School.
    Mehr anzeigen Weniger anzeigen
    34 Min.
  • Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series

    Jonathan Drachman, Neoleukin Therapeutics - Part of the Nametag Series
    Dec 14 2020
    Jonathan is a seasoned clinician, researcher, and biopharmaceutical executive who joined Neoleukin at the company’s founding in 2018. For 14 years prior, he was at Seattle Genetics, where he most recently served as Chief Medical Officer and Executive Vice President of Research and Development. From 1998 to 2004, Dr. Drachman was a faculty member of the Division of Hematology at the University of Washington in Seattle, and a Senior Investigator in the Division of Research and Education at Puget Sound Blood Center. He currently serves on the board of directors for Calithera Biosciences and Harpoon Therapeutics. Dr. Drachman received a BA in Biochemistry from Harvard University and an MD from Harvard Medical School. He completed his residency in internal medicine and fellowship in medical oncology at the University of Washington.
    Mehr anzeigen Weniger anzeigen
    44 Min.
  • Dale Chappell, Humanigen - Part of the Nametag Series

    Dale Chappell, Humanigen - Part of the Nametag Series
    Dec 14 2020
    - Founder, Black Horse Capital Advisors - Decades of biotechnology investment experience - HHMI Fellow, National Cancer Institute, Rosenberg Lab - Multiple publications in T-cell therapy, GM-CSF and immunology pathways
    Mehr anzeigen Weniger anzeigen
    25 Min.
Noch keine Rezensionen vorhanden